medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-8-30-33medsovet-612Research ArticleОНКОЛОГИЯ И ОНКОГЕМАТОЛОГИЯONCOLOGY AND ONCOHEMATOLOGYМедикаментозная кастрация в лечении распространенных форм рака предстательной железы. Роль бусерелинаMedical castration in the treatment of widespread cancers of the prostate. The role of buserelinМишугинС. В.MishuginSVnoemail@neicon.ruМордовинА. А.MordovinAAnoemail@neicon.ruГрицкевичА. А.GritskevichAAnoemail@neicon.ruРусаковИ. Г.RusakovIGnoemail@neicon.ruГБУЗ ГКБ №57, г. МоскваRussian FederationКраевой онкологический диспансер, г. КраснодарRussian Federation201430122014083033Copyright © Мишугин С.В., Мордовин А.А., Грицкевич А.А., Русаков И.Г., 20142014Мишугин С.В., Мордовин А.А., Грицкевич А.А., Русаков И.Г.Mishugin S., Mordovin A., Gritskevich A., Rusakov I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/612

Одним из важных направлений в лечении местно-распространенной и метастатической форм рака предстательной железы (РПЖ) является медикаментозная кастрация с применением агонистов ЛГРГ. Статья посвящена эффективности синтетического агониста ЛГРГ бусерелина (Бусерелин-депо) в лечении пациентов с гормонозависимым РПЖ. Применение Бусерелина-депо приводит к уменьшению уровня простат-специфического антигена, обеспечивает стабильное снижение уровня тестостерона сыворотки крови до посткастрационного уровня, уменьшение объема предстательной железы и симптомов нарушения мочеиспускания при отсутствии серьезных побочных эффектов.

Medical castration with LHRH agonists is a significant trend in the treatment of locally advanced and metastatic prostate cancer (PC). The article is devoted to the effectiveness of synthetic LHRH agonist buserelin (Buserelin-depo) in the treatment of patients with hormone dependent PC. Administration of Buserelin-depot results in a decrease of the prostate-specific antigen levels, stable reduction of serum testosterone to postcastration level, reduction in the size of the prostate and fewer voiding dysfunction symptoms without any serious side effects.

рак предстательной железымедикаментозная кастрацияагонисты ЛГРГбусерелинprostate cancermedical castrationLHRH agonistsbuserelinReferencesКаприн АД., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году. М., 2014.Каприн АД., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году. М., 2014.Каприн АД., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013.Каприн АД., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013.Huggins C, Hodges CV. Studies on prostatic cancer. II The effect of castration, estrogen and androgen injections on serum. Cancer Res, 1944, 1: 293-297.Huggins C, Hodges CV. Studies on prostatic cancer. II The effect of castration, estrogen and androgen injections on serum. Cancer Res, 1944, 1: 293-297.Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology, 2000, 56: 1021-4.Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology, 2000, 56: 1021-4.Evans CP, Fleshner N, Fitzpatrick JM et al. An evidence-base approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int, 2005, 95: 742-9.Evans CP, Fleshner N, Fitzpatrick JM et al. An evidence-base approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int, 2005, 95: 742-9.Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic rewiew and meta-analysis. Annals of Internal Medicine, 2000, 132, 7: 566-577.Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic rewiew and meta-analysis. Annals of Internal Medicine, 2000, 132, 7: 566-577.Anderson J, Abrahamsson PA, Crawford D et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int, 2008, 101:1497-1501.Anderson J, Abrahamsson PA, Crawford D et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy. BJU Int, 2008, 101:1497-1501.Heidenreich A, Pfister D, Ohlamann CH et al. Androgen deprivation for advanced prostate cancer. Urologe, 2008, 47: 270-83.Heidenreich A, Pfister D, Ohlamann CH et al. Androgen deprivation for advanced prostate cancer. Urologe, 2008, 47: 270-83.Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/ orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol, 1988;11 (Suppl. 2): S17-S182.Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/ orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol, 1988;11 (Suppl. 2): S17-S182.Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer, 1988, 62: 1881-7.Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer, 1988, 62: 1881-7.Bruun E, Frimodt-Moller C. The effect of buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The “Danish Buserelin Study Group”. Scand J Urol Nephrol, 1996, 30: 291-7.Bruun E, Frimodt-Moller C. The effect of buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The “Danish Buserelin Study Group”. Scand J Urol Nephrol, 1996, 30: 291-7.

The authors declare that there are no conflicts of interest present.